To systematically evaluate the association between specific DNA repair gene polymorphisms, particularly those in xeroderma pigmentosum (XP) and excision repair cross-complementing (XRCC) genes, and leukemia risk.
Key Findings:
No significant associations for ERCC1 C118T or XPD Asp312Asn.
ERCC1 8092C>A showed significant associations in homozygous and dominant models.
XPD Lys751Gln polymorphism demonstrated significant associations across all models.
Significant associations identified for XPC Lys939Gln and XPF Arg415Gln in specific models.
XRCC1 Arg194Trp, XRCC1 Arg399Gln, and XRCC3 Thr241Met polymorphisms were significantly associated with leukemia risk.
XPG 3507G>C showed no significant association.
Interpretation:
Several DNA repair polymorphisms are associated with increased leukemia susceptibility, and differential expression patterns suggest their potential role in risk stratification and biomarker development.
Limitations:
The study may be limited by the quality and heterogeneity of included studies, which could affect the robustness of the findings.
Potential publication bias in the meta-analysis.
Conclusion:
The findings suggest that specific DNA repair gene polymorphisms are linked to leukemia risk, highlighting the need for further research into their functional implications.
Morristown Medical Center now offers patients access to innovative clinical trials for immunotherapies including the use of Chimeric Antigen Receptor T Cells (CAR-T) and Tumor Infiltrating Lymphocytes (TIL).
